Epidermal growth factor receptor (EGFR) mutations are commonly found in patients with NSCLC, making EGFR tyrosine kinase inhibitors (TKIs) a cornerstone of targeted therapy [2,3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.